Remygen -Controlled Release Tablet
Remygen® is a controlled release tablet consisting of the active pharmaceutical ingredient GABA. The GABA substance is chemically synthesized in a well-controlled GMP process together with a global contract manufacturer. The manufacturing process is scalable and pediatric formulations with the same properties can be designed.
Remygen® is a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 diabetes. Remygen® is based on GABA, a key cell signalling molecule in the islets of Langerhans found in the pancreas.
Stimulating growth of insulin producing cells
Preclinical data indicate the potential of GABA to stimulate growth and function of insulin producing beta cells. The effect is primarily achieved by increasing the levels of GABA in the blood, thereby activating GABA receptors that affect the function and growth of insulin producing cells in the pancreas.
Reversing progression of diabetes
By stimulating the growth and function of insulin producing beta cells, Remygen® has the potential to reverse the progression of autoimmune diabetes and type 2 diabetes. Remygen® is in Phase I/II clinical development.